Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact

Christopher Haddad, Luca Guarnera, Yasuo Kubota, Carlos Bravo-Perez, Carmelo Gurnari, Olisaemeka Ogbue, Arda Durmaz, Serhan Unlu, Aashray Mandala, Mark Orland, Zachary Brady, Kartik Lakhotiya, Matteo D'Addona, Ishani Nautiyal, David S. Bosler, Hetty E. Carraway, Yogen Saunthararajah, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 1328.

https://doi.org/10.1182/blood-2024-210419

Published: 2024

Journal Articles

RUNX1 Germline Mutations of Autosomal-Dominant Familial Platelet Disorder Are More Common Than Expected in Adult Myeloid Leukemias Indicating Highly Variable Penetrance

Christopher Haddad, Yasuo Kubota, Carlos Bravo-Perez, Carmelo Gurnari, Luca Guarnera, Olisaemeka Ogbue, Arda Durmaz, Ishani Nautiyal, Aashray Mandala, David S. Bosler, Hetty E. Carraway, Yogen Saunthararajah, Valeria Visconte, Jaroslaw P. Maciejewski

Blood (2023) 142 (Supplement 1): 2736.

https://doi.org/10.1182/blood-2023-189420

Published: 2023

Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2023-185379

Published: 2023

Journal Articles

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Blood (2021) 138 (26): 2781–2798.

https://doi.org/10.1182/blood.2021012900

Published: 2021

Includes: Supplemental data

Journal Articles

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Blood (2021) 138 (19): 1885–1895.

https://doi.org/10.1182/blood.2020010603

Published: 2021

Includes: Supplemental data

Journal Articles

β-Hemoglobinopathies lead the way

Yogen Saunthararajah

Blood (2021) 137 (12): 1567–1569.

https://doi.org/10.1182/blood.2020009961

Published: 2021

Journal Articles

the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes

Hideki Makishima, MD PhD FACP., Tetsuichi Yoshizato, MD PhD, Kenichi Yoshida, MD PhD, Mikkael A. Sekeres, MD MS, Tomas Radivoyevitch, PhD, Hiromichi Suzuki, MD PhD, Bartlomiej P Przychodzen, MSc, Yasunobu Nagata, MD, PhD, Manja Meggendorfer, PhD, Masashi Sanada, MD PhD, Yusuke Okuno, MD PhD, Cassandra M. Hirsch, BSc, Teodora Kuzmanovic, Yusuke Shiozawa, MD, Yusuke Sato, MD PhD, Aiko Sato-Otsubo, Thomas LaFramboise, PhD, Naoko Hosono, MD, PhD, Yuichi Shiraishi, PhD, Kenichi Chiba, BA, Claudia Haferlach, MD, Wolfgang Kern, MD, Hiroko Tanaka, BA, Ines Gómez-Seguí, MD PhD, Holleh Husseinzadeh, MD, Swapna Thota, MD, Kathryn M. Guinta, Brittney Dienes, Tsuyoshi Nakamaki, MD, Shuichi Miyawaki, MD PhD, Yogen Saunthararajah, MD, Shigeru Chiba, MD, PhD, Satoru Miyano, PhD, Lee-Yung Shih, MD, Torsten Haferlach, MD, Seishi Ogawa, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP

Blood (2016) 128 (22): 4287.

https://doi.org/10.1182/blood.V128.22.4287.4287

Published: 2016

Journal Articles

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

Sudhakiranmayi Kuravi, M.S., Preethi Kunchala, M.S., Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Yogen Saunthararajah, MD, Kojo S. J. Elenitoba-Johnson, MD, Jensen Roy, MD, Joseph McGuirk, DO, Ramesh Balusu, PhD

Blood (2016) 128 (22): 4127.

https://doi.org/10.1182/blood.V128.22.4127.4127

Published: 2016

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD, PhD, M.P.H., Paul Elson, PhD, Samjhana Bogati, BSN, Ashley Woltman, BSN, RN, John Desamito, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Anjali S. Advani, Yogen Saunthararajah, MD, Jaroslaw P Maciejewski, MD PhD FACP, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 447.

https://doi.org/10.1182/blood.V128.22.447.447

Published: 2016

Journal Articles

The Role of LUC7L2 in Splicing and MDS

Courtney Elizabeth Hershberger, BS, Naoko Hosono, MD, PhD, Jarnail Singh, PhD, Rosemary C Dietrich, M.S., Xiaorong Gu, PhD, Hideki Makishima, MD PhD FACP., Yogen Saunthararajah, MD, Jaroslaw P Maciejewski, MD PhD FACP, Richard A Padgett, PhD

Blood (2016) 128 (22): 5504.

https://doi.org/10.1182/blood.V128.22.5504.5504

Published: 2016

Journal Articles

Germline Variants of RUNX-1 in Myeloid Malignancy

Alek d Nielsen, B.S., Sayer Alharbi, PhD, Cassandra M. Hirsch, BSc, Bartlomiej P Przychodzen, MSc, Mikkael A. Sekeres, MD MS, Yogen Saunthararajah, MD, Hetty E. Carraway, MD MBA, Jaroslaw P Maciejewski, MD PhD FACP

Blood (2016) 128 (22): 3926.

https://doi.org/10.1182/blood.V128.22.3926.3926

Published: 2016

Journal Articles

Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis

Surbhi Sidana, MD, Paul Elson, PhD, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD

Blood (2015) 126 (23): 2507.

https://doi.org/10.1182/blood.V126.23.2507.2507

Published: 2015

Journal Articles

Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012)

Blood (2015) 126 (23): 4491.

https://doi.org/10.1182/blood.V126.23.4491.4491

Published: 2015

Journal Articles

Prognostic Impact of Molecular Mutations in AML at First Relapse

Anjali S. Advani, MD, Paul Elson, PhD, Valeria Visconte, PhD, Jennifer S. Carew, PhD, Jaime Fensterl, Bartlomiej Przychodzen, MSc, Mikkael A. Sekeres, MD MS, Cassandra M Hirsch, Alek Nielsen, John Desamito, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MD MS, Betty K. Hamilton, MD, Sudipto Mukherjee, MD PhD, Ronald M. Sobecks, MD, Matt Kalaycio, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2015) 126 (23): 3825.

https://doi.org/10.1182/blood.V126.23.3825.3825

Published: 2015

Journal Articles

Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing

Blood (2015) 126 (23): 709.

https://doi.org/10.1182/blood.V126.23.709.709

Published: 2015

Journal Articles

The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice

Shuaiying Cui, Kim-Chew Lim, Lihong Shi, Mary Lee, Natee Jearawiriyapaisarn, Greggory Myers, Andrew Campbell, David Harro, Shigeki Iwase, Raymond C. Trievel, Angela Rivers, Joseph DeSimone, Donald Lavelle, Yogen Saunthararajah, James Douglas Engel

Blood (2015) 126 (3): 386–396.

https://doi.org/10.1182/blood-2015-02-626259

Published: 2015

Includes: Supplemental data

Journal Articles

Targets of opportunity for precision medicine

Yogen Saunthararajah

Blood (2015) 125 (20): 3041–3042.

https://doi.org/10.1182/blood-2015-04-638270

Published: 2015

Journal Articles

Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial

Blood (2014) 124 (21): 978.

https://doi.org/10.1182/blood.V124.21.978.978

Published: 2014

Journal Articles

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

Donald Lavelle, PhD, Michel Gowhari, DO, Michael Pacini, PharmD, Lani Krauz, RN, Johara Hassan, MD, Vinzon Ibanez, Maria A. Ruiz, MSc, Daisy Pacelli, BSc, Chaher Alhandalous, MD, Mitch A. Phelps, PhD, Kathleen Fenner, BS,MS, Reda Z. Mahfouz, MDPhD, John Barnard, Lewis L. Hsu, MD PhD, Victor R. Gordeuk, MD, Joseph DeSimone, PhD, Yogen Saunthararajah, MD, Robert E. Molokie, MD

Blood (2014) 124 (21): 90.

https://doi.org/10.1182/blood.V124.21.90.90

Published: 2014

NARROW

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact

RUNX1 Germline Mutations of Autosomal-Dominant Familial Platelet Disorder Are More Common Than Expected in Adult Myeloid Leukemias Indicating Highly Variable Penetrance

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

β-Hemoglobinopathies lead the way

the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

The Role of LUC7L2 in Splicing and MDS

Germline Variants of RUNX-1 in Myeloid Malignancy

Survival Outcomes of Leukemias and Myelodysplastic Syndromes Occurring As Second Cancers in the United States: A SEER Registry-Based Population Analysis

Real World Outcomes of Less Well-Characterized Acute Leukemias: A Population-Based Survival Analysis Using SEER Registry (1973-2012)

Prognostic Impact of Molecular Mutations in AML at First Relapse

Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing

The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice

Targets of opportunity for precision medicine

Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only